PRODUCTS

DIPYRIDAMOLE

Dipyridamole is a yellow crystalline powder that is practically insoluble in water and has the molecular formula C24H40N8O4.
Dipyridamole is also known by names such as 2,6-Bis(diethanolamino)-4,8-dipiperidino-pyrimido[5,4-d]pyrimidine and is identified by CAS No. 58-32-2.
Dipyridamole contains a pyrimido-pyrimidine ring system with piperidine and diethanolamino groups in its structure.

CAS Number: 58-32-2
Molecular Formula: C24H40N8O4
Molecular Weight: 504.63
EINECS Number: 200-374-7

Synonyms: Chlordiazepoxide, Chlorodiazepoxide, Chloradiazepoxide, Clopoxide, Chloridiazepide, Chlozepid, Methaminodiazepoxide, Chlordiazepoxidum, Chlordiazepoxydum, Clordiazepoxido, Clordiazepossido, Librium, Elenium, Libritabs, Librelease, Radepur, Lygen, Decacil, Helogaphen, Kalmocaps, Viopsicol, Control, Disarim, Ifibrium, Librinin, Menrium, Mesural, Mildmen, Napoton, Psicosan, Risolid, Silibrin, Tropium, Zetran, Eden-Psich, Sonimen, Zeisin, Balance, Novo-Poxide, Klopoxid, Librocol, Poxidium, Alpoxid, Defobin, Chlordiazepoxide HCl, Chlordiazep-oxide HCl, 7-Chloro-2-(methylimino)-5-phenyl-2,3-dihydro-4H-1,4-benzodiazepin-4-ol, 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide, 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-, 4-oxide, 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine, 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide, 3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide, 7-Chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxide, 7-Chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide, 7-Chloro-2-(methylamino)-5-phenyl-3H-benzo[e][1,4]diazepine 4-oxide, 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepin-4-ium-4-olate, Dipyridamole (200 mg);2,2',2'',2'''-((4,8-Di(piperidin-1-yl)pyrimido[5,4-d]-pyrimidine-2,6-diyl)bis(azanetriyl))tetraet, Corosan;Coroxin, Curantyl, Dipyridamine;Dipyridan;Dipyudamine

Dipyridamole that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively.
Dipyridamole a vasodilator agent, it inhibits the formation of blood clots.
Dipyridamole is a synthetic medication belonging to the antiplatelet and vasodilator group of drugs.

These functional groups influence its solubility, chemical behavior, and interaction with biological targets.
The molecule has a relatively high molecular weight of approximately 504.63 g/mol.
Dipyridamole was originally developed for its vasodilating properties.

Dipyridamole was later found to have important effects on platelet function, which led to its use in cardiovascular medicine.
Dipyridamole is mainly associated with preventing abnormal blood clot formation and with certain diagnostic procedures.

Dipyridamole works partly by increasing the concentration of adenosine around cells.
Dipyridamole inhibits enzymes and transport processes involved in the breakdown and uptake of adenosine, allowing adenosine-mediated effects to become more pronounced.
This contributes to relaxation of blood vessels and changes in platelet activity.

The drug also affects platelet aggregation.
Platelets are blood cells that stick together during the formation of a blood clot.
Dipyridamole reduces platelet activation and aggregation, helping decrease the tendency for platelets to form clumps.

Dipyridamole has therefore been used as an antiplatelet agent.
Dipyridamole has historically been prescribed to reduce the risk of thrombotic complications in patients with certain cardiovascular conditions.
Its antiplatelet effect is particularly relevant when excessive platelet aggregation could contribute to blockage of blood vessels.

One important medical use of dipyridamole has been in combination with anticoagulant therapy.
For example, modified-release dipyridamole has been used together with aspirin for secondary prevention of certain ischemic strokes and transient ischemic attacks.
The combination works through different mechanisms to reduce the formation of unwanted blood clots.

Dipyridamole has also been used in cardiac stress testing.
Because it produces vasodilation in the coronary circulation, it can be administered when a patient cannot perform sufficient physical exercise for a conventional exercise stress test.
Dipyridamole increases coronary blood flow and can help reveal differences in blood supply between healthy and diseased areas of the heart.

During pharmacological stress testing, dipyridamole can produce coronary vasodilation.
Healthy coronary vessels may increase blood flow substantially, while vessels supplied by significantly narrowed arteries may not respond in the same way.
Imaging performed during the test can then help physicians evaluate myocardial perfusion.

Dipyridamole has also been used in myocardial perfusion imaging.
Dipyridamole can act as a pharmacological stress agent before certain nuclear imaging procedures.
This allows doctors to assess blood flow through the coronary circulation without requiring strenuous exercise from the patient.

Dipyridamole has also been studied for its effects on the cardiovascular system beyond platelet inhibition.
Its vasodilatory properties can influence blood flow and vascular resistance.
However, its clinical role depends on the formulation, dose, and medical indication.

Dipyridamole is available in different pharmaceutical formulations.
These have included immediate-release tablets, modified-release capsules, and injectable preparations for specific medical applications.
The formulation affects how quickly the active substance becomes available in the body.

Modified-release dipyridamole formulations are designed to release the drug gradually.
This allows therapeutic concentrations to be maintained for longer periods than with some immediate-release formulations.
Such formulations can be used when prolonged antiplatelet activity is required.

Dipyridamole is also important in pharmaceutical research and drug development.
Its effects on adenosine metabolism, platelet function, and vascular signaling have made it a useful compound for studying cardiovascular physiology.
Researchers have also investigated its potential effects in other biological systems.

Dipyridamole has been investigated for possible antiviral, anti-inflammatory, and other biological effects.
These investigations are related to its influence on cellular signaling pathways and nucleotide metabolism.
However, experimental findings should not be interpreted as established clinical uses.

Dipyridamole has also attracted research interest because of its interaction with adenosine signaling.
Adenosine is involved in several physiological processes, including vascular regulation and cellular signaling.
By affecting adenosine availability, dipyridamole can influence several downstream biological responses.

The drug is absorbed from the gastrointestinal tract after oral administration.
Its absorption can be affected by the formulation and by physiological conditions in the digestive system.
Dipyridamole is extensively metabolized, with glucuronidation being an important metabolic pathway.

Dipyridamole is highly protein bound in the bloodstream.
Dipyridamole undergoes metabolism primarily in the liver, and its metabolites are eliminated mainly through the bile and feces.
Only a relatively small amount of unchanged drug is eliminated through the kidneys.

The chemical has relatively low water solubility, which is an important consideration in pharmaceutical formulation.
Formulation scientists use different approaches to achieve suitable dissolution and absorption.
The physical properties of the compound therefore influence how it is prepared for therapeutic use.

Dipyridamole has a characteristic yellow to orange-yellow appearance in its pure form.
Its physical properties are important when evaluating pharmaceutical-grade material and during quality-control testing.
Analytical methods such as high-performance liquid chromatography can be used to identify and quantify the compound.

The compound is commonly identified by its CAS Registry Number 58-32-2.
Dipyridamoles chemical identity can also be described using systematic nomenclature and pharmaceutical reference standards.
These identifiers are useful when purchasing raw materials, preparing analytical standards, or conducting pharmaceutical research.

Dipyridamole has been manufactured as an active pharmaceutical ingredient (API) for use in cardiovascular medicines.
Pharmaceutical manufacturers formulate the API with excipients to produce tablets, capsules, or other dosage forms.
The finished formulation must meet appropriate pharmaceutical quality and stability requirements.

Dipyridamole has also been used in combination medicines.
One important combination is dipyridamole with aspirin, where the two active ingredients provide complementary antiplatelet effects.
Such combination therapy is intended to reduce the likelihood of recurrent vascular events in selected patients.

Dipyridamole is not a general-purpose chemical used in industrial applications.
Dipyridamoles primary importance is in pharmaceutical and biomedical applications, particularly those involving platelet function and coronary blood-flow regulation.
Its chemical structure and pharmacological activity have made it a well-established compound in cardiovascular medicine.

From a chemical perspective, dipyridamole is an organic heterocyclic compound containing several nitrogen atoms and hydroxyl groups.
Dipyridamoles multiple nitrogen-containing rings contribute to its interaction with biological molecules and influence its physicochemical properties.
The hydroxyl groups also provide sites for chemical modification and conjugation reactions.

Dipyridamole has been studied using a range of analytical techniques, including HPLC, mass spectrometry, spectroscopy, and chromatographic methods.
These techniques are useful for pharmaceutical quality control and for measuring the compound in biological samples.
Analytical characterization is particularly important because pharmaceutical formulations contain several other ingredients alongside the active compound.

The compound can undergo chemical degradation under unsuitable storage conditions.
Temperature, light, moisture, and formulation conditions can influence the stability of pharmaceutical preparations.
For this reason, commercial products are stored according to the conditions specified by the manufacturer.

Dipyridamole should not be confused with a conventional blood thinner that directly inhibits coagulation factors.
Its principal pharmacological action is antiplatelet and vasodilatory rather than direct anticoagulation.
This distinction is important because platelet inhibition and coagulation inhibition involve different parts of the blood-clotting process.

Dipyridamole is a pharmaceutical compound mainly associated with antiplatelet therapy and pharmacological cardiac stress testing.
Dipyridamoles ability to inhibit platelet aggregation and increase adenosine-mediated vasodilation accounts for most of its established medical applications.
Because it is an active drug rather than an ordinary industrial chemical, its handling, formulation, and use are governed by pharmaceutical quality and safety requirements.

Melting point: 165-166 °C (lit.)
Boiling point: 593.96°C (rough estimate)
Density: 1.2046 (rough estimate)
refractive index: 1.6910 (estimate)
storage temp.: room temp
solubility: DMSO: soluble
form: powder
pka: pKa 6.4 (Uncertain)
color: yellow
Water Solubility: Soluble in chloroform, methanol, dilute acids, ethanol. Slightly soluble in water.
Merck: 14,3346
Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
InChI: InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
InChIKey: IZEKFCXSFNUWAM-UHFFFAOYSA-N

Dipyridamole is a synthetic medication belonging to the antiplatelet and vasodilator group of drugs.
Dipyridamole is a yellow crystalline powder that is practically insoluble in water and has the molecular formula C24H40N8O4.
Dipyridamole is also known by names such as 2,6-Bis(diethanolamino)-4,8-dipiperidino-pyrimido[5,4-d]pyrimidine and is identified by CAS No. 58-32-2.

Dipyridamole contains a pyrimido-pyrimidine ring system with piperidine and diethanolamino groups in its structure.
These functional groups influence its solubility, chemical behavior, and interaction with biological targets.
The molecule has a relatively high molecular weight of approximately 504.63 g/mol.

Dipyridamole was originally developed for its vasodilating properties.
Dipyridamole was later found to have important effects on platelet function, which led to its use in cardiovascular medicine.
Today, dipyridamole is mainly associated with preventing abnormal blood clot formation and with certain diagnostic procedures.

Dipyridamole works partly by increasing the concentration of adenosine around cells.
It inhibits enzymes and transport processes involved in the breakdown and uptake of adenosine, allowing adenosine-mediated effects to become more pronounced.
This contributes to relaxation of blood vessels and changes in platelet activity.

Dipyridamole has also been used in cardiac stress testing.
Because it produces vasodilation in the coronary circulation, it can be administered when a patient cannot perform sufficient physical exercise for a conventional exercise stress test.
It increases coronary blood flow and can help reveal differences in blood supply between healthy and diseased areas of the heart.

The drug is absorbed from the gastrointestinal tract after oral administration.
Its absorption can be affected by the formulation and by physiological conditions in the digestive system.
It is extensively metabolized, with glucuronidation being an important metabolic pathway.

Dipyridamole is commonly identified by its CAS Registry Number 58-32-2.
Its chemical identity can also be described using systematic nomenclature and pharmaceutical reference standards.
These identifiers are useful when purchasing raw materials, preparing analytical standards, or conducting pharmaceutical research.

From a chemical perspective, dipyridamole is an organic heterocyclic compound containing several nitrogen atoms and hydroxyl groups.
Its multiple nitrogen-containing rings contribute to its interaction with biological molecules and influence its physicochemical properties.
The hydroxyl groups also provide sites for chemical modification and conjugation reactions.

Dipyridamole can undergo chemical degradation under unsuitable storage conditions.
Temperature, light, moisture, and formulation conditions can influence the stability of pharmaceutical preparations.
For this reason, commercial products are stored according to the conditions specified by the manufacturer.

Dipyridamole is a pharmaceutical compound mainly associated with antiplatelet therapy and pharmacological cardiac stress testing.
Its ability to inhibit platelet aggregation and increase adenosine-mediated vasodilation accounts for most of its established medical applications.
Because it is an active drug rather than an ordinary industrial chemical, its handling, formulation, and use are governed by pharmaceutical quality and safety requirements.

Dipyridamole is a synthetic pyrimidopyrimidine derivative that has been studied for many years because of its effects on blood vessels and platelets.
Its structure contains several nitrogen-rich heterocyclic groups together with piperidine rings and hydroxyethyl substituents.
This combination gives the molecule distinctive physicochemical properties and contributes to its interaction with several biological pathways.

The molecular formula of dipyridamole is C24H40N8O4, and its molecular weight is approximately 504.63 g/mol.
Dipyridamole has a highly nitrogen-containing structure, with multiple tertiary amine groups that can become protonated.
This affects its behavior in different pH environments and is important when developing pharmaceutical formulations.

Dipyridamole is generally described as a yellow or yellow-orange crystalline solid.
It has very limited solubility in water, which can make formulation development challenging.
Pharmaceutical manufacturers therefore use specific formulation technologies to obtain consistent drug release and absorption.

The molecule has several hydroxyl groups that can participate in hydrogen bonding.
These groups contribute to the compound's intermolecular interactions and physical properties.
The nitrogen atoms in the molecule also provide sites that influence its basicity and interaction with biological molecules.

Dipyridamole has a relatively complex three-dimensional molecular structure.
Its piperidine rings provide flexible portions of the molecule, while the fused heterocyclic core gives it a more rigid central structure.
The balance between these structural features contributes to its pharmacological behavior.

One of the most important properties of dipyridamole is its ability to inhibit phosphodiesterase enzymes.
Phosphodiesterases normally break down intracellular signaling molecules such as cyclic AMP and cyclic GMP.
By inhibiting certain phosphodiesterase activities, dipyridamole can increase intracellular levels of these signaling molecules.

In platelets, increased cyclic AMP contributes to reduced platelet activation.
When platelets are less readily activated, they are less likely to aggregate with one another.
This mechanism contributes to the antiplatelet effect of the drug.

Dipyridamole also inhibits the uptake of adenosine by cells.
As a result, adenosine can remain available for longer in the extracellular environment.
Adenosine can activate receptors on vascular and other cells, producing several physiological effects.

The interaction with adenosine is particularly important during pharmacological cardiac stress testing.
Dipyridamole increases blood flow through normal coronary arteries by promoting vasodilation.
Areas supplied by significantly narrowed coronary arteries may not increase their blood flow to the same extent.

This difference in blood flow can be detected using myocardial perfusion imaging.
Dipyridamole therefore provides a way to create cardiovascular stress without requiring a patient to perform intense physical exercise.
Other pharmacological stress agents, including adenosine and regadenoson, are also used for similar purposes.

Dipyridamole can cause vasodilation in the coronary circulation.
This effect is one reason the compound was originally investigated as a cardiovascular drug.
Its ability to modify coronary blood flow remains useful in diagnostic medicine.

The drug has historically been used to reduce the risk of thromboembolic events.
Its antiplatelet action can reduce the formation of platelet-rich blood clots in appropriate clinical situations.
Dipyridamole has particularly been used in secondary prevention after certain ischemic cerebrovascular events.

Dipyridamole has been formulated together with aspirin for antiplatelet treatment.
Aspirin inhibits platelet cyclooxygenase activity, while dipyridamole works through different pathways.
The combination therefore provides antiplatelet effects through complementary mechanisms.

A commonly known pharmaceutical formulation is extended-release dipyridamole combined with aspirin.
The modified-release design allows dipyridamole to be delivered over an extended period.
This formulation has been used for prevention of recurrent ischemic stroke and transient ischemic attack in selected patients.

Dipyridamole is also available in formulations intended for intravenous administration in diagnostic procedures.
The intravenous route allows the drug to produce its vasodilatory effect relatively quickly.
Medical staff can monitor the patient during pharmacological stress testing because the drug can produce cardiovascular effects.

During a cardiac stress procedure, dipyridamole may cause headache, flushing, dizziness, chest discomfort, or shortness of breath.
These effects are related mainly to its vasodilatory and adenosine-related activity.
Medical personnel can manage the effects during a controlled diagnostic procedure.

Aminophylline or another appropriate adenosine antagonist may be used to reverse excessive dipyridamole-related effects in certain clinical settings.
This is possible because the pharmacological effects of dipyridamole are closely related to increased extracellular adenosine activity.
The decision to reverse the effect is made by medical professionals according to the clinical situation.

Dipyridamole has also been investigated in platelet function research.
Because it changes platelet signaling without directly destroying platelets, it has been useful for studying mechanisms involved in platelet activation and aggregation.
Laboratory studies have examined its effects on cyclic nucleotide pathways and adenosine signaling.

Researchers have also investigated dipyridamole in vascular biology.
Dipyridamoles effects on endothelial cells, smooth-muscle cells, and extracellular adenosine have made it useful for studying vascular responses.
These studies have helped explain some of its cardiovascular effects.

Dipyridamole has been investigated for potential anti-inflammatory properties.
The mechanisms proposed for these effects include changes in extracellular adenosine and intracellular signaling.
However, these research findings do not mean that dipyridamole is routinely prescribed as a general anti-inflammatory drug.

Dipyridamole has also attracted interest in immunological research.
Adenosine signaling can influence the activity of immune cells, and dipyridamole can alter extracellular adenosine availability.
Researchers have therefore investigated its effects in different experimental models.

Dipyridamole has been studied in relation to viral infections as well.
Some laboratory and experimental studies have examined whether it can influence viral replication or host-cell signaling.
These findings are mainly of research interest and should not be interpreted as evidence that dipyridamole is an established antiviral treatment.

The drug has also been examined in cellular and molecular biology research.
Dipyridamoles ability to interfere with nucleoside transport and phosphodiesterase activity makes it useful for investigating intracellular signaling.
Researchers can use dipyridamole as a pharmacological tool to modify adenosine-related pathways.

Dipyridamole can inhibit equilibrative nucleoside transporters, particularly pathways involved in cellular uptake of adenosine.
This mechanism increases extracellular adenosine concentrations.
The resulting changes in adenosine receptor activation can affect vascular tone and cellular signaling.

Dipyridamoles effect on nucleoside transport has made dipyridamole useful as a research compound.
Scientists can use it experimentally to investigate how cells transport adenosine and related nucleosides.
This is separate from its clinical use as a pharmaceutical drug.

Dipyridamole has also been studied in connection with thrombosis research.
Platelet activation plays an important role in arterial thrombosis, especially when a damaged or diseased blood vessel is present.
Understanding how dipyridamole modifies platelet behavior helps researchers study potential strategies for preventing platelet-rich thrombi.

Dipyridamole has a relatively high lipophilicity compared with many simple water-soluble drugs, although its ionizable groups strongly influence its apparent solubility.
This makes the relationship between pH, ionization, and formulation particularly important.
Pharmaceutical scientists consider these properties when developing oral dosage forms.

Because dipyridamole is a weakly basic compound with several nitrogen atoms, its ionization state changes with pH.
The ionized and non-ionized forms can differ in solubility and membrane permeability.
This is one reason why its pharmaceutical behavior can vary depending on the formulation environment.

Dipyridamole can form salts or different solid-state forms under suitable conditions.
Solid-state properties can influence dissolution, stability, and manufacturing behavior.
Pharmaceutical development therefore includes characterization of the active ingredient's physical form.

Dipyridamole can be analyzed by high-performance liquid chromatography (HPLC).
HPLC methods are commonly useful for determining the amount of active pharmaceutical ingredient in raw materials and finished dosage forms.
Chromatographic methods can also be used to monitor degradation products.

Liquid chromatography–mass spectrometry (LC-MS) can provide additional information about dipyridamole and its metabolites.
The mass spectrum can help identify the molecular ion and related compounds.
This type of analysis is particularly useful in pharmaceutical and pharmacokinetic research.

Spectroscopic techniques can also contribute to structural identification and quality control.
Infrared spectroscopy can provide information about functional groups, while nuclear magnetic resonance spectroscopy can help confirm molecular structure.
These methods are often used alongside chromatographic analysis rather than as replacements for it.

Dipyridamole undergoes extensive metabolism in the body.
Glucuronidation is an important metabolic pathway, producing conjugated metabolites.
Most of the drug and its metabolites are ultimately eliminated through the biliary and fecal routes.

The pharmacokinetic behavior of dipyridamole depends on its formulation.
Immediate-release and modified-release products can produce different concentration–time profiles.
This is why different formulations are not necessarily interchangeable on a simple dose-for-dose basis.

Food can also influence the absorption of some oral dipyridamole formulations.
The exact effect depends on the formulation and how the product is designed to release the active ingredient.
For this reason, pharmaceutical products are normally taken according to their specific prescribing instructions.

Dipyridamole has a relatively long history in cardiovascular pharmacology.
Its development illustrates how a compound initially studied for one cardiovascular effect can later find an important role through a different mechanism.
The discovery of its effects on platelet aggregation contributed significantly to its later clinical applications.

Dipyridamole is not primarily used as a painkiller, antibiotic, or conventional anticoagulant.
Its main established roles are related to platelet inhibition and pharmacological vasodilation.
This distinction is important when describing its pharmaceutical classification.

Dipyridamole is also different from drugs such as warfarin or heparin, which act directly on components of the coagulation system.
Dipyridamole mainly affects platelet behavior and vascular signaling.
For this reason, the terms antiplatelet and anticoagulant should not be used interchangeably when describing the compound.

From a manufacturing perspective, dipyridamole is produced as a pharmaceutical active ingredient under controlled conditions.
Manufacturers must control factors such as purity, residual solvents, impurities, particle characteristics, and stability.
The finished API is then used to prepare pharmaceutical dosage forms.

Dipyridamole is particularly relevant to the pharmaceutical and biomedical industries.
Dipyridamole is supplied as an active ingredient, analytical reference material, and research compound.
Its applications are much more closely associated with medicine and laboratory research than with conventional industrial chemical manufacturing.

Dipyridamole is a chemically complex nitrogen-containing pharmaceutical compound with antiplatelet, vasodilatory, phosphodiesterase-inhibiting, and adenosine-related activities.
Its established applications include prevention of certain thrombotic events and use as a pharmacological stress agent for cardiac perfusion studies, while its other biological effects continue to be investigated in research.
Dipyridamoles chemistry, low water solubility, metabolism, and multiple biological targets make it an important compound in pharmaceutical formulation, cardiovascular medicine, and biomedical research.

Uses:
Selective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation
Dipyridamole is known as a coronary vasodilating agent, although it also possesses specific antiaggregant activity.
Dipyridamole is used for preventing thrombo-formation after cardiac valve replacement in combination with warfarin.

Dipyridamole prevents platelets sticking to the replacement heart valve and causing a blood clot on the valve.
Dipyridamole is used to dilate blood vessels in people with peripheral arterial disease and coronary artery disease.
Dipyridamole has been shown to suppress high glucose-induced osteopontin mRNA expression and protein secretion, as well as inhibit cAMP and cGMP hydrolysis.

Research indicates that Dipyridamole is a non-specific nucleoside transport inhibitor with the ability to increase the effects of adenosine in sinoatrial and atrioventricular nodes.
Dipyridamole is an inhibitor of ENT1 and ENT2.

Dipyridamole is mainly used as an antiplatelet medicine to reduce the tendency of platelets to stick together and form unwanted blood clots.
Dipyridamole is particularly used in the prevention of certain ischemic vascular events, where a blood clot can reduce or block blood flow to the brain or other tissues.
Its antiplatelet activity makes it an established compound in cardiovascular and cerebrovascular medicine.

One of its important uses is in the secondary prevention of ischemic stroke.
Dipyridamole can be prescribed to reduce the risk of another stroke in patients who have previously experienced certain types of ischemic cerebrovascular events.
Dipyridamole is often used in combination with aspirin in appropriate patients.

Dipyridamole is also used for prevention of transient ischemic attacks (TIAs).
A TIA occurs when blood flow to part of the brain is temporarily interrupted, often because of a small clot or vascular disease.
By reducing platelet aggregation, dipyridamole can help lower the likelihood of further platelet-related vascular events.

A well-known pharmaceutical use is the combination of dipyridamole and aspirin.
The two drugs inhibit platelet function through different mechanisms, providing a combined antiplatelet effect.
Modified-release dipyridamole/aspirin formulations have been used for secondary prevention after certain ischemic cerebrovascular events.

Dipyridamole is also used as a pharmacological stress agent in cardiac testing.
Instead of asking a patient to exercise intensely, physicians can administer dipyridamole to increase coronary blood flow.
This makes it possible to evaluate myocardial perfusion in patients who cannot adequately perform an exercise stress test.

Dipyridamole is used before certain types of myocardial perfusion imaging.
Dipyridamole produces vasodilation in the coronary circulation, increasing blood flow through healthy coronary vessels.
Areas supplied by significantly narrowed arteries may show a different response, allowing abnormalities in coronary perfusion to be detected.

Dipyridamole has been used with nuclear cardiac imaging techniques.
After pharmacological stress is produced, a radioactive imaging agent can be used to visualize blood flow through the heart muscle.
The resulting images can help physicians investigate suspected coronary artery disease.

Another use is in pharmacological stress echocardiography, although other agents are more commonly selected for this purpose depending on the clinical situation.
The vasodilatory effect of dipyridamole can alter coronary blood flow and myocardial perfusion.
Its use depends on the diagnostic protocol and the patient's medical condition.

Dipyridamole can be administered intravenously for diagnostic cardiovascular procedures.
The intravenous route provides controlled delivery and allows the pharmacological effect to develop during the examination.
Medical staff monitor patients because temporary cardiovascular symptoms can occur during the test.

The compound is also used as a research tool in platelet biology.
Researchers use dipyridamole to investigate mechanisms involved in platelet activation and aggregation.
Its effects on cyclic nucleotide signaling provide a way to study platelet responses under controlled laboratory conditions.

Dipyridamole is used in adenosine-signaling research.
It inhibits cellular uptake of adenosine, which increases the availability of extracellular adenosine.
Researchers can therefore use it to investigate how adenosine receptors influence vascular and cellular responses.

Dipyridamole is also used experimentally as an inhibitor of equilibrative nucleoside transport.
This property allows researchers to study how cells transport adenosine and related nucleosides across their membranes.
Such experiments are relevant to pharmacology, cell biology, and biochemical research.

Dipyridamole is used in phosphodiesterase research.
It can inhibit certain phosphodiesterase enzymes involved in the breakdown of cyclic nucleotides.
Researchers use this activity to investigate signaling pathways involving cyclic AMP and cyclic GMP.

Another use is in vascular pharmacology research.
Because dipyridamole affects adenosine availability and vascular smooth-muscle signaling, it can be used to study mechanisms controlling blood-vessel dilation.
This makes it useful in laboratory studies of vascular physiology.

Dipyridamole has been investigated in anti-inflammatory research.
Changes in extracellular adenosine signaling can influence inflammatory pathways and immune-cell activity.
Researchers have therefore examined dipyridamole in experimental models involving inflammation.

The compound has also been investigated for immunomodulatory effects.
Adenosine signaling can regulate several types of immune-cell responses.
Dipyridamole's ability to modify extracellular adenosine concentrations has made it a useful experimental compound in this field.

Dipyridamole has been investigated in antiviral research as well.
Laboratory studies have examined whether its effects on cellular pathways could influence viral replication or host responses.
These investigations are experimental and do not mean that dipyridamole is routinely used as a general antiviral medicine.

Dipyridamole has also been studied in cancer research.
Researchers have investigated dipyridamole because nucleoside transport and intracellular signaling are important in cancer-cell biology.
However, these studies represent research applications rather than an established cancer treatment.

Dipyridamole has been used experimentally in studies of endothelial-cell function.
The endothelium plays an important role in regulating blood-vessel tone and vascular health.
By altering extracellular adenosine and intracellular signaling, dipyridamole can be used to investigate endothelial responses.

Dipyridamole is also used in thrombosis research.
Researchers can examine how changes in platelet signaling affect clot formation under laboratory conditions.
Dipyridamole provides a pharmacological method for reducing platelet activity in these experiments.

Dipyridamole can be used as a reference compound in pharmaceutical research.
Its well-characterized pharmacological activity makes it useful when developing analytical methods or studying antiplatelet mechanisms.
Researchers may compare new compounds with dipyridamole when investigating platelet-related activity.

Dipyridamole is also used as an analytical reference standard in pharmaceutical laboratories.
HPLC and LC-MS methods can be developed using known quantities of dipyridamole to identify and quantify the compound.
This is important for quality control of pharmaceutical products.

Dipyridamole is used in pharmaceutical formulation research because its low water solubility presents formulation challenges.
Researchers investigate particle size, solid-state properties, excipients, and drug-release systems to achieve consistent performance.
These studies are particularly relevant to modified-release oral formulations.

Dipyridamole can also be used in drug-delivery research.
Scientists investigate different approaches to improve its dissolution, absorption, and release characteristics.
This includes research into modified-release and other formulation technologies.

Dipyridamole has been investigated in combination-drug research.
Its different mechanism of platelet inhibition makes it suitable for studies examining complementary antiplatelet therapies.
The dipyridamole–aspirin combination is the most established example of this approach.

Dipyridamole can also be used in preclinical pharmacology studies.
Animal and laboratory models may be used to investigate its effects on blood flow, platelet function, vascular signaling, and drug metabolism.
These studies help researchers understand pharmacological mechanisms before developing new therapeutic approaches.

Dipyridamole is used in pharmacokinetic studies to investigate absorption, distribution, metabolism, and elimination.
Researchers can measure the parent compound and its metabolites in biological samples.
This information helps characterize how different formulations behave in the body.

Dipyridamole is also used in bioanalytical method development.
Laboratories can develop sensitive chromatographic and mass-spectrometric methods for measuring dipyridamole in plasma or other biological matrices.
Such methods are useful in pharmaceutical development and pharmacokinetic research.

Another application is quality control of finished pharmaceutical products.
Manufacturers analyze tablets, capsules, and other formulations to verify the amount of dipyridamole present.
Testing can also detect degradation products and other impurities.

Dipyridamole is used in the development of extended-release pharmaceutical products.
Because the drug can be formulated to release gradually, pharmaceutical scientists can study different release profiles and excipient combinations.
The goal is to maintain an appropriate drug exposure over an extended period.

Dipyridamole is also relevant to cardiovascular drug-development research.
Its established effects on platelet aggregation and coronary blood flow provide a basis for comparing new compounds that act on related pathways.
Researchers can use it as a pharmacological reference when evaluating experimental antiplatelet agents.

Dipyridamole has been investigated for possible applications involving microcirculation and tissue blood flow.
Its vasodilatory activity can increase blood flow under certain experimental conditions.
These effects have been studied in vascular and physiological research.

Dipyridamole has also been investigated in relation to kidney and renal vascular research.
Because adenosine signaling influences renal blood flow and vascular tone, dipyridamole can be used experimentally to modify this pathway.
Such studies are mainly intended to understand physiological mechanisms.

Dipyridamole can be used in laboratory studies of platelet adhesion and aggregation.
Researchers can compare platelet behavior in the presence and absence of the compound.
This helps characterize how signaling pathways influence platelet responses.

Dipyridamole has also been used in research involving blood–vessel interactions.
Platelets, endothelial cells, and vascular smooth muscle communicate through several signaling molecules, including adenosine and cyclic nucleotides.
Dipyridamole can be used experimentally to modify these pathways and investigate their effects.

Another use is in drug-interaction research.
Because dipyridamole affects platelet function and vascular signaling, researchers can investigate how it behaves when combined with other cardiovascular medicines.
These studies are important for understanding pharmacological compatibility and potential additive effects.

Dipyridamole is also used in chemical and pharmaceutical reference collections.
Pure material can be maintained as a reference substance for identification, analytical testing, and research.
This is especially useful in pharmaceutical laboratories and quality-control environments.

In pharmaceutical manufacturing, dipyridamole serves primarily as an active pharmaceutical ingredient rather than an industrial chemical additive.
Dipyridamole is incorporated into medicines designed for specific cardiovascular and cerebrovascular indications.
The API must meet strict requirements for identity, purity, potency, and stability.

Dipyridamoles are antiplatelet therapy and pharmacological cardiovascular stress testing, while additional uses occur in pharmaceutical, biochemical, and biomedical research.
Dipyridamole is particularly important in medicines intended to reduce the risk of certain recurrent ischemic events and in diagnostic procedures that evaluate coronary blood flow.
Its effects on adenosine uptake, phosphodiesterase activity, platelet signaling, and vascular dilation also make it a useful research compound in pharmacology and cardiovascular science.

Safety Profile:
Poison by intraperitoneal and intravenous routes.
Moderately toxic by ingestion and subcutaneous routes.
Human systemic affects cardiomyopathy including infarction.

Dipyridamole used as a coronary vasodilator.
Dipyridamole is a pharmacologically active pharmaceutical compound, so it should be handled as a chemical substance rather than as an ordinary laboratory material.

Exposure to the pure compound or concentrated pharmaceutical material may produce unwanted biological effects.
The actual hazard classification can vary depending on the formulation, concentration, and applicable regulatory system.

Dipyridamole can cause skin irritation in some individuals after direct contact.
Repeated or prolonged contact with the powder may increase the possibility of irritation.
Laboratory personnel should avoid unnecessary skin exposure when handling the active ingredient.

Direct contact with the eyes should also be avoided.
Dust or particles of dipyridamole may cause eye irritation, including redness, watering, and discomfort.
Safety glasses should be worn when handling the powder or preparing concentrated solutions.

Inhalation of dipyridamole dust should be minimized.
Handling the dry material can generate airborne particles, particularly during weighing, transferring, or mixing.
Inhalation may irritate the respiratory tract, and work should preferably be carried out with suitable ventilation.

Dipyridamole can be harmful if swallowed in inappropriate quantities.
Because it is a biologically active drug, excessive exposure can produce pharmacological effects rather than simply acting as an inert chemical.
Accidental ingestion should therefore be treated seriously and referred to appropriate medical or poison-control guidance.

One of the main pharmacological hazards associated with dipyridamole is excessive vasodilation.
The compound increases adenosine-related activity and can cause blood vessels to dilate.
This can result in headache, flushing, dizziness, or a temporary decrease in blood pressure.

Dipyridamole can cause hypotension, particularly when relatively high doses are administered or when it is used as a pharmacological stress agent.
A significant reduction in blood pressure can cause weakness, dizziness, or fainting.
For this reason, intravenous dipyridamole used during cardiac testing is administered under medical supervision.

Supply Of Dipyridamole:
For further information about Dipyridamole, including available product grades, technical specifications, application suitability and supply options, please contact Ataman Kimya.